Anti-IgE (omalizumab): A new therapeutic approach for chronic rhinosinusitis

References 

1. Pleis JR, Coles R. Summary health statistics for U.S. adults: National Health Interview Survey, 1998. Vital Health Stat 10. 2002;209:1–113
2. Fokkens W, Lund V, Bachert C, Clement P, Helllings P, Holmstrom M, et al. EAACI position paper on rhinosinusitis and nasal polyps executive summary. Allergy. 2005;5:583–601
3. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2005 Update. NIH publication no. 02-3659. Available at: http://www.ginasthma.org. Accessed August 26, 2006.
4. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet. 2006;9537:780–793
5. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006;25:2689–2695
6. Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH. Anti-IgE for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006;2;CD003559
7. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;7:709–717